SPYRE THERAPEUTICS, INC. Revenue from Grants (Deprecated 2018-01-31)
SPYRE THERAPEUTICS, INC. (SYRE) reported Revenue from Grants (Deprecated 2018-01-31) of $1.51 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromGrants · last filed 2018-05-08
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.51M, a 53.77% increase year-over-year.
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.48M, a 18.93% increase year-over-year.
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.26M, a 9.75% increase year-over-year.
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $1.48M, a 7.72% increase year-over-year.
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2017 was $5.21M, a 12.47% increase from fiscal 2016.
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2016 was $4.63M, a 23.94% decline from fiscal 2015.
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2015 was $6.08M.
- SPYRE THERAPEUTICS, INC. revenue from grants (deprecated 2018-01-31) for fiscal 2014 was $0.00.
| Period end | Revenue from Grants (Deprecated 2018-01-31) 3 month | Revenue from Grants (Deprecated 2018-01-31) 6 month | Revenue from Grants (Deprecated 2018-01-31) 9 month | Revenue from Grants (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $1.51M 10-Q · filed 2018-05-08 | $2.99M derived: sum of 2 quarters · filed 2018-05-08 | $4.25M derived: sum of 3 quarters · filed 2018-05-08 | $5.73M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | $1.48M 10-K · filed 2018-03-13 | $2.74M derived: sum of 2 quarters · filed 2018-03-13 | $4.22M derived: sum of 3 quarters · filed 2018-03-13 | $5.21M 10-K · filed 2018-03-13 |
| 2017-09-30 | $1.26M 10-K · filed 2018-03-13 | $2.74M derived: sum of 2 quarters · filed 2018-03-13 | $3.72M 10-Q · filed 2017-11-07 | $4.97M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | $1.48M 10-K · filed 2018-03-13 | $2.46M 10-Q · filed 2017-08-09 | $3.71M derived: sum of 3 quarters · filed 2018-05-08 | $4.86M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | $982.00K 10-Q · filed 2018-05-08 | $2.23M derived: sum of 2 quarters · filed 2018-05-08 | $3.38M derived: sum of 3 quarters · filed 2018-05-08 | $4.75M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $1.25M 10-K · filed 2018-03-13 | $2.40M derived: sum of 2 quarters · filed 2018-03-13 | $3.77M derived: sum of 3 quarters · filed 2018-03-13 | $4.63M 10-K · filed 2018-03-13 |
| 2016-09-30 | $1.15M 10-K · filed 2018-03-13 | $2.52M derived: sum of 2 quarters · filed 2018-03-13 | $3.38M 10-Q · filed 2017-11-07 | $4.97M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $1.37M 10-K · filed 2018-03-13 | $2.23M 10-Q · filed 2017-08-09 | $3.82M derived: sum of 3 quarters · filed 2018-03-13 | $4.89M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | $859.00K 10-K · filed 2018-03-13 | $2.44M derived: sum of 2 quarters · filed 2018-03-13 | $3.52M derived: sum of 3 quarters · filed 2018-03-13 | $6.94M derived: sum of 4 quarters · filed 2018-03-13 |
| 2015-12-31 | $1.58M 10-K · filed 2017-03-23 | $2.66M derived: sum of 2 quarters · filed 2017-03-23 | $6.08M derived: sum of 3 quarters · filed 2017-03-23 | $6.08M 10-K · filed 2018-03-13 |
| 2015-09-30 | $1.07M 10-K · filed 2017-03-23 | $4.50M derived: sum of 2 quarters · filed 2017-03-23 | $4.50M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $3.43M 10-K · filed 2017-03-23 | $3.43M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-19 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |